We synthesized a series of bortezomib derivatives that showed CIP2A inhibition activity, and the inhibition of CIP2A-Akt signaling pathway correlated with the cytotoxicity of these derivatives in HCC cells. The gene discussed is AKT1; the disease is hepatocellular carcinoma.